Mesoblast Reports Strong H1 FY2026 Results, Driven by Ryoncil® Launch

Successful commercial launch of Ryoncil® generates $48.7 million in revenue, supporting investment in R&D and pipeline expansion

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Mesoblast Limited, a global leader in allogeneic cellular medicines, reported strong financial and operational results for the first half of fiscal year 2026. The successful commercial launch of its product Ryoncil® generated $48.7 million in revenue, allowing the company to invest in R&D, including a Phase 3 trial for a chronic low back pain indication, as well as commercial manufacturing and launch of a second-generation product.

Why it matters

Mesoblast's performance highlights the potential of its allogeneic cellular medicine platform to address significant unmet medical needs and generate sustainable commercial success. The Ryoncil® launch and pipeline expansion demonstrate the company's ability to translate its scientific expertise into viable products and drive long-term shareholder value.

The details

Mesoblast reported total revenue of $51.3 million for H1 FY2026, driven by $48.7 million in Ryoncil® sales after gross-to-net adjustments. Ryoncil® gross profit, excluding amortization, was $44.2 million. The company was able to invest in R&D, including for a Phase 3 trial in chronic low back pain, as well as commercial manufacturing and a second-generation product launch. Mesoblast reported a net loss of $40.2 million, an improvement of $7.8 million year-over-year, and ended the period with a cash balance of $130 million.

  • Mesoblast received a specific HCPCS J-Code from CMS for Ryoncil® on October 1, 2025, resulting in growth of Ryoncil® usage under CMS coverage versus commercial coverage in the last quarter.
  • Mesoblast's second randomized controlled Phase 3 trial in chronic discogenic low back pain is on track to complete its 300-patient enrollment target in March/April 2026.

The players

Mesoblast Limited

A global leader in allogeneic cellular medicines for inflammatory diseases, developing therapies from its proprietary mesenchymal lineage cell therapy technology platform.

Ryoncil®

Mesoblast's FDA-approved mesenchymal stromal cell (MSC) therapy for the treatment of steroid-refractory acute graft versus host disease in pediatric patients.

Dr. Silviu Itescu

Mesoblast's Chief Executive Officer, commenting on the company's strong operational and financial performance.

Got photos? Submit your photos here. ›

What they’re saying

“Today we report strong operational and financial performance for the first half of FY2026, a period that marks an important inflection point in Mesoblast's evolution from clinical development to sustainable commercial execution.”

— Dr. Silviu Itescu, Chief Executive Officer (Mesoblast Press Release)

What’s next

Mesoblast intends to expand the clinical indications of Ryoncil® for life-cycle extension in both adults and children with life-threatening inflammatory conditions. The final protocol design for the Phase 3 trial of Ryoncil® as part of the second-line treatment regimen in adults with steroid-refractory acute graft versus host disease will be provided to the Institutional Review Board in March for site initiation.

The takeaway

Mesoblast's strong financial and operational performance, driven by the successful commercial launch of Ryoncil®, positions the company to further invest in its pipeline and drive long-term growth. The company's ability to translate its scientific expertise into viable products demonstrates the potential of its allogeneic cellular medicine platform to address significant unmet medical needs.